Replies to post #13999 on Moderna Inc (MRNA)

[jondoeuk]

From this: ''A phase 3 trial involving 407 patients, combining IO102/IO103 and pembrolizumab (Keytruda) in metastatic melanoma, will read out in the third quarter of 2025 (NCT05155254). The company expects to file a Biologics License Application with FDA by year’s end.

This comes more than 3 years after promising phase 1/2 data appeared in Nature Medicine.'' https://www.ajmc.com/view/from-super-skeptical-beginnings-a-new-immune-modulatory-vaccine-awaits-phase-3-results

IO102 targets IDO1 and IO103 targets PD-L1.